American Association for Cancer Research, 2022
ATYR2810 an Anti-NRP2 Monoclonal Antibody Targets Tumor Associated Macrophages
Society for Immunotherapy of Cancer, 2021
Engineering an Anti-Neuropilin-2 (NRP2) Antibody that Selectively Blocks NRP2 Interactions with Semaphorin and Plexin
Antibody Engineering & Therapeutics Europe, 2021
ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy
Keystone Symposia: Cancer Stem Cells, 2021
The Neuropilin-2 Targeting Antibody ATYR2810 Inhibits Non-Small Cell Lung Cancer Tumor Growth in Monotherapy and Combination Therapy
American Association for Cancer Research, 2021
A Domain-Specific Antibody to NRP2 Down-Regulated Epithelial-Mesenchymal Transition Genes and Enhanced Efficacy of Standard-of-Care Therapeutics for Aggressive Breast Cancer
American Association for Cancer Research, 2021
Neuropilin-2 is Expressed on Immune Cells Present in the Tumor Microenvironment, and May Contribute to the Suppression of Immune Regulation Leading to Progression and Metastasis of Cancer
Keystone Symposia: Tumor Metabolism and the Microenvironment, 2021
Domain-Specific Antibodies to Neuropilin 2 Implicate VEGF-C and not Semaphorin 3F in Breast Cancer Stem Cell Function
American Association for Cancer Research, 2020
The N-terminal domain of HARS is a novel NRP2 ligand and can regulate NRP2-dependent macrophage function
American Association for Cancer Research, 2019